Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN versus NITROFURANTOIN MACROCRYSTALLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN versus NITROFURANTOIN MACROCRYSTALLINE.
CHLOROMYCETIN vs NITROFURANTOIN MACROCRYSTALLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit multiple bacterial enzymes involved in carbohydrate metabolism, including acetyl-CoA synthetase, and disrupt cell wall synthesis.
50-100 mg/kg/day IV divided every 6 hours; maximum 4 g/day. Topical: apply to affected area 2-4 times daily.
100 mg orally twice daily for 5-7 days (uncomplicated UTI); 100 mg orally every 12 hours for 10-14 days (pyelonephritis: not first-line).
None Documented
None Documented
1.5-4 hours in adults; prolonged to 3-7 hours in neonates and 4-12 hours in hepatic impairment; clinical context: dose adjustment required in liver disease.
Terminal half-life: 20-60 minutes (short, requires q6h dosing for therapeutic efficacy).
Renal: 5-10% unchanged; hepatic glucuronidation (90%) followed by renal elimination of metabolites; small biliary excretion (<5%) and fecal elimination.
Renal: 30-40% excreted unchanged in urine. Biliary/fecal: minimal; remainder metabolized or eliminated via other routes.
Category C
Category D/X
Antibiotic
Antibiotic